GlobeNewswire

HEINEKEN statement in response to announcement from Distell in South Africa

Share

Amsterdam, 18 May 2021 - Heineken N.V. notes the announcement from Distell Group Holdings Limited (Distell) and confirms that it is currently engaged with Distell regarding a potential transaction. Discussions are ongoing, but note that there can be no certainty that an agreement will be reached. Further announcements will be made as appropriate.

-ENDS-

Press enquiries
Sarah Backhouse / Michael Fuchs                                                         
E-mail: pressoffice@heineken.com                        
Tel: +31-20-5239-355                                

Investor and analyst enquiries
Federico Castillo Martinez / Janine Ackermann / Robin Achten
E-mail: investors@heineken.com
Tel: +31-20-5239-590

About HEINEKEN
HEINEKEN is the world's most international brewer. It is the leading developer and marketer of premium beer and cider brands. Led by the Heineken® brand, the Group has a portfolio of more than 300 international, regional, local and specialty beers and ciders. HEINEKEN is committed to innovation, long-term brand investment, disciplined sales execution and focused cost management. Through "Brewing a Better World", sustainability is embedded in the business. HEINEKEN has a well-balanced geographic footprint with leadership positions in both developed and developing markets. It employs more than 80,000 employees and operates breweries, malteries, cider plants and other production facilities in more than 70 countries. Heineken N.V. and Heineken Holding N.V. shares trade on the Euronext in Amsterdam. Prices for the ordinary shares may be accessed on Bloomberg under the symbols HEIA NA and HEIO NA and on Reuters under HEIN.AS and HEIO.AS. HEINEKEN has two sponsored level 1 American Depositary Receipt (ADR) programmes: Heineken N.V. (OTCQX: HEINY) and Heineken Holding N.V. (OTCQX: HKHHY). Most recent information is available on HEINEKEN’s website, and follow us on LinkedIn, Twitter and Instagram.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Karolinska Developments portföljbolag Aprea Therapeutics uppnår primärt utfallsmått i kombinationsterapi av AML med eprenetapopt17.6.2021 10:25:55 CEST | Pressemelding

STOCKHOLM, SVERIGE 17 juni 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Aprea Therapeutics rapporterar positiva resultat från en pågående fas 1/2-studie av bolagets läkemedelskandidat eprenetapopt i kombination med venetoklax och azacitidin i patienter med TP53-muterad akut myeloisk leukemi, AML. Studieresultaten visar att behandlingen uppnår studiens förutbestämda primära effektmått med fullständig remission i 37% av de utvärderade fallen. Studieresultaten baseras på en analys av 30 evaluerbara patienter där fullständig remission (CR) uppmättes i 37% av fallen. Den sammanlagda remissionsfrekvensen i kombination med ofullständig remission (CRi), CR/Cri, var 53%. Enligt studiens tillämpade design (Simon 2-stage) uppnåddes därmed det förutbestämda primära effektmåttet avseende fullständig remission. I den fortsatta delen av fas 1/2-studien ingår elva patienter som erhåller kombinationsterapin och monitoreras avseende säkerhet och behandlingse

Karolinska Development’s portfolio company Aprea Therapeutics lead candidate drug eprenetapopt reaches primary efficacy endpoint in combination therapy of acute myeloid leukemia17.6.2021 10:25:55 CEST | Press release

STOCKHOLM, SWEDEN – June 17, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Aprea Therapeutics has reported positive outcomes in an ongoing Phase 1/2 study evaluating the efficacy of the company’s candidate drug eprenetapopt in combination with venteoclax and azacitidine in patients treated for TP53 mutated acute myeloid leukemia, AML. The results show that the primary efficacy endpoint of complete remission was reached in 37% of patients. The results are underpinned by an analysis performed on 30 evaluable patients, demonstrating complete remission in 37% of the cases. the composite response rate, i.e. CR combined with CR with incomplete hematologic recovery (CRi), CR/CRi, was 53%. The pre-defined primary efficacy endpoint concerning complete remission was thus reached in accordance with the applied study design (Simon’s 2-stage). Eleven patients remain on the study treatment and is continuously monitored on safety and efficacy para

RESULT OF RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS17.6.2021 10:10:00 CEST | Press release

RESULT OF RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS Auction date2021-06-17Loan192Coupon1.00 %ISIN-codeSE0010133207Maturity2023-03-15 Tendered volume, SEK mln800 +/- 400 Volume offered, SEK mln1,600Volume bought, SEK mln800Number of bids2Number of accepted bids1Average yield-0.064 %Lowest accepted yield-0.064 %Highest yield-0.064 %% accepted at lowest yield 100.00 Auction date2021-06-17Loan1588Coupon1.50 %ISIN-codeSE0011063015Maturity2024-03-01 Tendered volume, SEK mln2,000 +/- 1,000 Volume offered, SEK mln5,500Volume bought, SEK mln2,000Number of bids6Number of accepted bids2Average yield0.032 %Lowest accepted yield0.031 %Highest yield0.034 %% accepted at lowest yield 62.50 Auction date2021-06-17Loan151 Coupon1.00 %ISIN-codeSE0013486156Maturity2030-06-12 Tendered volume, SEK mln700 +/- 350 Volume offered, SEK mln1,600Volume bought, SEK mln700Number of bids4Number of accepted bids3Average yield0.853 %Lowest accepted yield0.851 %Highest yield0.861 %% accepted at lowest yield 71.43 Auc

Nokia accelerates Telenor and Telia joint 5G network rollout in Denmark17.6.2021 10:00:00 CEST | Press release

Press Release Nokia accelerates Telenor and Telia joint 5G network rollout in Denmark Nokia to accelerate rollout following the availability of 3.5GHz spectrum; the enhanced services will offer premium 5G speeds to customers The move builds upon Nokia’s long-standing partnership with TTN as lead supplier of 5G RAN Radio 17 June 2021 Espoo, Finland – Nokia continues to build upon its ongoing business with leading Danish mobile operators, Telenor and Telia via their joint network (TTN) accelerating the delivery of 5G services nationwide following the availability of 3.5 GHz spectrum. Nokia is the exclusive supplier of 5G RAN and will support the modernization of the shared network ensuring TTN’s three million customers have the best connectivity experiences. The availability of spectrum in the 3.5GHz band will offer incredibly fast 5G speeds to customers. The modernization deal will focus initially on Denmark’s four largest cities before expanding to cover most Danish customers during 20

Share Buyback Transaction Details June 10 – June 16, 202117.6.2021 10:00:00 CEST | Press release

Share Buyback Transaction Details June 10– June 16,2021 June 17, 2021 - Wolters Kluwer today reports that it has repurchased 68,486of its own ordinary shares in the period from June 10, 2021, up to and including June 16, 2021, for €5.6million and at an average share price of €81.21. These repurchases are part of the share buyback program announced on February 24, 2021, under which we intend to repurchase shares for up to €350 million during 2021. The cumulative amounts repurchased to date under this program are as follows: Share Buyback 2021 PeriodCumulative shares repurchased in period Total consideration (€ million)Average share price (€)2021 to date 2,697,810191.971.13 For the period starting May 6, 2021, up to and including August 2, 2021, we have engaged a third party to execute €70 million of buybacks on our behalf, within the limits of relevant laws and regulations (in particular Regulation (EU) 596/2014) and the company’s Articles of Association. Repurchased shares are added to

Board of Directors Declares Share Buyback17.6.2021 08:33:39 CEST | Press release

17 June 2021 Board of Directors Declares Share Buyback On 16 June 2021, Acron’s Board of Directors resolved that the Company repurchase its outstanding shares as envisaged by clause 2, Article 72 of the Federal Law On Joint-Stock Companies. The number of shares sought shall not exceed 4,053,400, which is 10 per cent of the authorised capital. The repurchase price shall be RUB 6,050 per share. Therefore, the buyback amount shall not exceed RUB 24.5 billion. Shareholders may apply for repurchase from 8 July 2021 through 6 August 2021 inclusive. The repurchased shares shall be paid on or before 21 August 2021. If the total number of shares tendered by the Company’s shareholders exceeds 4,053,400, shares shall be repurchased from selling shareholders on a pro rata basis. A notification of the share buyback shall be posted on the Company’s website at https://www.acron.ru/en on or before 17 June 2021. Media contacts: Sergey Dorofeev Anastasia Gromova Tatiana Smirnova Public Relations Phone:

Eurocastle Announces 2021 AGM Results and PDMR Dealing Notification17.6.2021 08:00:00 CEST | Press release

Contact: Oak Fund Services (Guernsey) Limited Company Administrator Attn: Mark Woodall Tel: +44 1481 723450 Eurocastle Announces 2021 AGM Resultsand PDMR Dealing Notification Guernsey, 17 June 2021 – Eurocastle Investment Limited (Euronext Amsterdam: ECT) (“Eurocastle” or the “Company”) today announces the results of its 2021 Annual General Meeting held yesterday, 16 June 2021. All ordinary and extraordinary business tabled before the meeting in accordance with the Notice of Annual General Meeting circulated to shareholders on 26 May 2021 was approved. A copy of this Notice is available on Eurocastle’s website at www.eurocastleinv.com under Periodic Reports and Shareholder Communications in the Investor Relations Section. In addition the Company issued 1,000 ordinary shares to each of its three independent directors as part of their in-place compensation arrangements. By reference to its obligations under Article 19 of EU Regulation 596/2014, the Company is making public the following